Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW HAVEN, Conn., March 10, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster,...
-
NEW HAVEN, Conn., Feb. 23, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
-
NEW HAVEN, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare...
-
NEW HAVEN, Conn., Dec. 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare...
-
NEW HAVEN, Conn., Nov. 17, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third...
-
Significant Evolution of Senior Leadership Team in 2015 Co-Founders Transition Company to Globally-Experienced Executives NEW HAVEN, Conn., Nov. 16, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd....
-
NEW HAVEN, Conn., Nov. 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare...
-
NEW HAVEN, Conn. and TEL AVIV, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with...
-
NEW HAVEN, Conn. and TEL AVIV, Israel, Oct. 26, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with...
-
NEW HAVEN, Conn., Oct. 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and...